Eli Lilly Just Announced Game-Changing News
Key PointsThe weight loss drug market has reached an important turning point.
Eli Lilly has announced groundbreaking developments in the weight loss drug market. The pharmaceutical giant, known for its diverse portfolio of treatments, has seen significant earnings growth thanks to a specific drug category. This market is projected to reach nearly $100 billion by 2030, and the focus is on weight loss drugs, especially those within the GLP-1 category.
Lilly's tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss, are injectable medications. The company has also received approval for its first oral weight loss drug, Foundayo. However, Lilly faces competition from Novo Nordisk, the original market leader with Ozempic and Wegovy. As Medicare coverage expands and oral weight loss drugs gain traction, both companies are striving to lead in this emerging market.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
